Rain Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Rhea-AI Summary

Rain Therapeutics reported a Q3 net loss of $18 million, slightly decreasing from $18.4 million in Q3 2021. The end of Q3 cash position stands at $90.7 million, bolstered by a recent $50 million stock offering, ensuring a cash runway into 2025. The Phase 3 MANTRA trial's topline data is expected in Q1 2023, while early data from the Phase 2 MANTRA-2 trial shows promising results in patients with MDM2-amplified cancers. The MANTRA-3 trial has been deprioritized to optimize resource allocation. Rain continues to advance its milademetan therapies.

Positive

• End of Q3 cash position of $90.7 million, enhanced by a recent $50 million offering.
• Encouraging preliminary interim data from Phase 2 MANTRA-2 trial, with two unconfirmed partial responses.
• Topline data for Phase 3 MANTRA trial expected in Q1 2023, indicating potential for future growth.

Negative

• Net loss of $18.0 million for Q3 2022, compared to $18.4 million in Q3 2021.
• Deprioritization of Phase 2 MANTRA-3 trial may indicate resource constraints.

– End of third quarter cash position of $90.7 million excludes the recent $50 million registered offering, and together, provide a cash runway into 2025 –

– Phase 3 pivotal MANTRA trial topline data now anticipated in first quarter of 2023 –

– Phase 2 MANTRA-2 trial preliminary interim data demonstrates encouraging monotherapy signal in ten evaluable patients; MANTRA-2 continues to enroll –

– Phase 2 MANTRA-3 trial deprioritized to rationalize use of financial resources –

– Phase 1/2 MANTRA-4 trial anticipated to commence in first quarter 2023 –

– Management to host conference call and webcast today at 5:00 PM Eastern Time –

NEWARK, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today reported financial results for the third quarter ended September 30, 2022, along with an update on the Company’s key developments, business operations and upcoming milestones.

“Rain continues to execute on our milademetan franchise with encouraging early interim data from our Phase 2 MANTRA-2 trial and anticipated near-term topline data from our Phase 3 registrational MANTRA trial next quarter,” said Avanish Vellanki, co-founder and chief executive officer of Rain. “The preliminary observations of monotherapy activity of milademetan in the MANTRA-2 trial demonstrates encouraging data in a novel biomarker-based tumor agnostic strategy and supporting potential in additional MDM2-dependent cancers.”

Dr. Robert Doebele, MD, PhD, president and chief scientific officer of Rain continued, “Preliminary data from the MANTRA-2 trial exhibited activity with two unconfirmed partial responses (PRs) at their first scan and promising tumor regression activity in two additional patients following milademetan monotherapy. We are very encouraged to see proof of concept activity using a genetic selection strategy across a diverse set of solid tumor types in heavily pre-treated patients, and those that possess multiple genetic co-alterations including strong oncogenic driver mutations. We believe the early activity suggests reactivation of p53 in MDM2-dependent cancers and may represent a sound therapeutic strategy with single-agent milademetan, and possibly through combination regimens as well.”

Dr. Richard Bryce, MBChB, chief medical officer of Rain continued, “We have also observed this promising activity from the MANTRA-2 trial in patients with MDM2 copy number above 8. Hence, we plan to revise the protocol to include patients tested locally for MDM2 copy number of 8 and greater and anticipate this will further enhance the pace of enrollment to expedite completion of the 65-patient trial. We plan to initiate the MANTRA-4 trial next quarter and remain very excited about this second tumor agnostic basket strategy.”

Key Corporate Updates and Upcoming Milestones

• $50.0 Million Registered Offering of Common Stock
  • Completed a $50.0 million registered offering of common stock and non-voting common stock on November 8, 2022
  • End of third quarter cash balance of $90.7 million excludes the $50.0 million registered offering
• Phase 3 MANTRA Trial of Milademetan in Dedifferentiated Liposarcoma
  • Topline data now anticipated in the first quarter of 2023
• Phase 2 Preliminary Interim Data for the MANTRA-2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors
  • As of October 26, 2022, ten patients were efficacy-evaluable with CN ≥8 by central testing
    • Two unconfirmed PRs were observed with tumor regression of 34% and 30% (pancreatic and lung cancer, respectively)
      • The patient with pancreatic cancer is pending response confirmation and ongoing treatment
      • The patient with lung cancer is deceased due to COVID-19
    • Two patients exhibited promising activity with tumor regression of 29% and 27% (biliary tract and breast cancer, respectively) and the patients are continuing with the investigational therapy
  • Observed rapid anti-tumor effect of milademetan in heavily pretreated, refractory patients, with a median of four prior therapies
  • Safety profile to date is preliminarily consistent with prior Phase 1 milademetan trial
• Phase 2 MANTRA-3 Trial in Merkel Cell Carcinoma Deprioritized
  • MANTRA-3 is deprioritized to rationalize use of financial and personnel resources
• Phase 1/2 MANTRA-4 Basket Trial in Advanced Solid Tumors Exhibiting Loss of the CDKN2A Gene
  • Commencement of MANTRA-4, the trial to evaluate the combination of milademetan with Roche’s FDA-approved IO therapy, atezolizumab, planned for first quarter of 2023
• Recent addition to our Scientific Advisory Board, Nicholas A. Saccomano, Ph.D. in September 2022
  • Dr. Saccomano is the former Chief Scientific Officer of Array Biopharma, and a seasoned leader and mentor with over 30 years of experience in pharmaceutical and biotechnology research and development
    

Our updated corporate presentation includes details of the preliminary interim data for MANTRA-2 and is available at the “Corporate Presentation” section of the Rain website.

Third Quarter Financial Results
For the three and nine months ended September 30, 2022, Rain reported a net loss of $18.0 million and $53.0 million, respectively, as compared to a net loss of $18.4 million and $33.4 million for the same periods in 2021, respectively.

Research and development (R&D) expenses were $14.5 million and $42.3 million for the three and nine months ended September 30, 2022, respectively, as compared to $15.3 million and $26.1 million for the same periods in 2021, respectively. The decrease for the three months ended September 30, 2022 as compared to the prior period was primarily due to the milestone fees to Daiichi Sankyo of $5.5 million incurred during the prior period, partially offset by various R&D costs for milademetan, as well as higher payroll-related costs for Rain’s R&D personnel. The increase for the nine-months ended September 30, 2022 as compared to the prior period was primarily driven by the ongoing MANTRA Phase 3 trial in liposarcoma and Phase 2 tumor-agnostic basket trial (MANTRA-2), as well as personnel costs and various other R&D costs for milademetan. Non-cash stock-based compensation expenses included in R&D expenses were approximately $0.7 million and $2.8 million in the three and nine months ended September 30, 2022, respectively, as compared to $0.7 million and $1.4 million in the same periods in 2021, respectively.

General and administrative (G&A) expenses were $3.9 million and $11.3 million for the three and nine months ended September 30, 2022, respectively, as compared to $3.2 million and $7.3 million for the same periods in 2021, respectively. The increases were primarily due to higher payroll-related costs for Rain’s G&A personnel, outside consulting, legal costs and various third-party G&A costs. Non-cash stock-based compensation expense included in G&A expenses were approximately $0.2 million and $0.8 million for the three and nine months ended September 30, 2022, as compared to $0.2 million and $0.4 million for each of the same periods in 2021.

Total non-cash stock-based compensation expense were approximately $0.9 million and $3.6 million for the three and nine months ended September 30, 2022, respectively, as compared to $0.9 million and $1.8 million for the same periods in 2021, respectively.

As of September 30, 2022, Rain had $90.7 million in cash, cash equivalents and short-term investments as compared to $140.2 million at December 31, 2021. On November 8, 2022, Rain completed a $50.0 million registered offering of common stock and non-voting common stock, and together with the cash balance as of September 30, 2022 provides cash runway into 2025.

As of September 30, 2022, Rain had approximately 26.6 million shares of common stock outstanding.

Third Quarter 2022 Results Conference Call and Webcast Details
The management of Rain Therapeutics will host a conference call and webcast for the investment community today, November 10, 2022 at 2:00 pm PT (5:00 pm ET). A live webcast may be accessed here. The conference call can be accessed by dialing 1 (877) 704-4453 (U.S. Toll Free) / 1 (201) 389-0920 (International). The passcode for the conference call is 13733093.

Replay of the call will be available by visiting the “Events” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About MANTRA-2

The MANTRA-2 trial is designed to evaluate the safety and efficacy of milademetan monotherapy in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy and that exhibit wild-type p53 and a prespecified minimum MDM2 gene copy number. Approximately 65 patients are anticipated to be enrolled to receive milademetan. As of the latest data cutoff on October 26, 2022, 17 patients have been enrolled. The primary endpoint of the trial is objective response rate as measured by RECIST criteria. Secondary endpoints include duration of response, disease control rate progression-free survival by investigator assessment, overall survival and growth modulation index.

About Milademetan

Milademetan (also known as RAIN-32) is an oral small molecule inhibitor of the MDM2-p53 complex that reactivates p53.Milademetan has demonstrated antitumor activity in an MDM2-amplified subtype of liposarcoma (LPS) and other solid tumors in a Phase 1 clinical trial, supported by a rationally designed dosing schedule to mitigate safety concerns and widen the potential therapeutic window of MDM2 inhibition. Rain has completed enrollment in a Phase 3 trial of milademetan (MANTRA) in patients with LPS, and is evaluating milademetan in a Phase 2 tumor-agnostic basket trial in certain solid tumors (MANTRA-2). Rain anticipates commencing a Phase 1/2 clinical trial to evaluate the safety, tolerability and efficacy of milademetan in combination with Roche’s atezolizumab in patients with loss of cyclin-dependent kinase inhibitor 2A (CDKN2A) and wildtype p53 advanced solid tumors (MANTRA-4), in the first quarter of 2023. Milademetan has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LPS.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Rain’s ongoing and planned trials for milademetan, including expected timing for the commencement of MANTRA-4, the efficacy and safety profile of milademetan, expected trial design, expected timing for topline data in MANTRA trial and the relationship between the results from the interim data from trial and results of future or ongoing clinical studies. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans,” “will”, “anticipates,” “goal,” “potential,” “expects” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rain’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rain’s business in general and limited operating history, Rain’s ability to execute on its strategy, Rain’s reliance on third parties to conduct and support its preclinical studies and clinical trials, positive results from a clinical trial, or interim data from an ongoing clinical trial, may not necessarily be predictive of the results of future or ongoing clinical studies, the effect of the COVID-19 pandemic on Rain’s clinical trials and business operations, the impact of general economic, health, industrial or political conditions in the United States or internationally, additional state and federal healthcare reform measures that could result in reduced demand for Rain’s product candidates, the sufficiency of Rain’s capital resources and its ability to raise additional capital, and the other risks described in Rain’s Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Rain undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact
Dan Ferry
LifeSci Advisors
617-430-7576
daniel@lifesciadvisors.com 

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

RAIN THERAPEUTICS INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except share and per share amounts)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2022				2021				2022				2021
Operating expenses:
Research and development	$	14,510			$	15,284			$	42,322			$	26,101
General and administrative		3,901				3,154				11,257				7,334
Total operating expenses		18,411				18,438				53,579				33,435
Loss from operations		(18,411	)			(18,438	)			(53,579	)			(33,435	)
Other income:
Interest income		370				11				533				25
Other income		—				1				—				1
Total other income, net		370				12				533				26
Net loss	$	(18,041	)		$	(18,426	)		$	(53,046	)		$	(33,409	)
Net loss per share, basic and diluted	$	(0.68	)		$	(0.70	)		$	(2.00	)		$	(1.96	)
Weighted-average shares used to compute net loss per share, basic and diluted		26,564,615				26,466,746				26,535,474				17,025,032

SUMMARY BALANCE SHEET DATA
(in thousands)
	September 30,			December 31,
	2022			2021(1)
	(unaudited)
Cash, cash equivalents and short-term investments	$	90,708		$	140,218
Total assets		94,635			147,140
Stockholders’ equity		81,409			130,504
(1) Derived from audited financial statements

FAQ

What were the financial results for Rain (RAIN) in Q3 2022?

Rain reported a net loss of $18 million for Q3 2022, which is a slight decrease from $18.4 million in Q3 2021.

What is the cash position of Rain (RAIN) at the end of Q3 2022?

As of September 30, 2022, Rain had a cash position of $90.7 million, which includes proceeds from a recent $50 million offering.

When will the topline data for the Phase 3 MANTRA trial be available?

Topline data for the Phase 3 MANTRA trial is anticipated in the first quarter of 2023.

What were the key findings from the Phase 2 MANTRA-2 trial for Rain (RAIN)?

The Phase 2 MANTRA-2 trial showed encouraging preliminary data with two unconfirmed partial responses and promising tumor regression in evaluable patients.

What changes have been made to Rain's clinical trial strategy?

The Phase 2 MANTRA-3 trial has been deprioritized to rationalize financial and personnel resources.